Coagulation/Hemostasis

Background: Coagulation is a tightly regulated process for limiting post-traumatic blood loss, however, when in pro-coagulant status it also contributes to vessel occlusive diseases, most notably thrombotic diseases of both arterial and venous system. We have developed several in vivo models and assays to identify the dynamic changes on the body’s hemostasis status, which act as remarkable endpoints for pharmacology/safety assessment in vascular disease models

Models: In vivo Bleeding, Arterio-Venous (A-V) shunt, Wessler stasis, FeCl3 induced arterial thrombosis

Standard study duration: hours, upon study endpoints

Clinical endpoint: Bleeding time/weight, Thrombus/clot weight, coagulation tests, blood flow velocity, thrombelastography…

Features: Hemostasis assessments, safety assessment, antithrombotic studies, coagulation factor studies, intravital thrombosis…

 

For more information about these models, please contact Mr. James Song, mailto:james.song@prisysbiotech.com

TOP